Afutuzumab
From Self-sufficiency
Revision as of 18:47, 27 July 2010 by PotatoBot (Talk) (Stub sorting and placement of stub template(s))
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Template:Infobox drug/mab source |
| Target | CD20 |
| Identifiers | |
| CAS Number | 949142-50-1 |
| ATC code | none |
| Chemical data | |
| Formula | C6512H10060N1712O2020S44 |
| Molar mass | 146.1 kDa[[Script error: No such module "String".]] |
Afutuzumab is a monoclonal antibody being developed by Hoffmann-La Roche Inc. for the treatment of lymphoma.[1] It acts as an immunomodulator.[2][3]
References
- ↑ Robak, T (2009). "GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies". Current opinion in investigational drugs (London, England : 2000). 10 (6): 588–96. PMID 19513948.
- ↑ Statement On A Nonproprietary Name Adopted By The Usan Council - Afutuzumab, American Medical Association.
- ↑ International Nonproprietary Names for Pharmaceutical Substances (INN), World Health Organization.
| 40x30px | This monoclonal antibody-related article is a stub. You can help ssf by expanding it. |
| 40px | This antineoplastic or immunomodulatory drug article is a stub. You can help ssf by expanding it. |
Categories:
- Pages with script errors
- Drugs that are a monoclonal antibody
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- 2Fix
- Hoffmann-La Roche
- Pages with broken file links
- Monoclonal antibody stubs
- Antineoplastic and immunomodulating drug stubs
